Essure Contraceptive Device MDL - 2739

  • Essure

When a product promises the sky but fails to deliver, one anticipates a legal battle between its users and manufacturer; Essure Coils have met with a similar fate. Essure® is an intrauterine device developed by Conceptus Inc., a subsidiary of Bayer AG, and approved by FDA in 2002. It was marketed as a permanent surgical sterilization option for women. This device is composed of two metal coils made from polyester fibers, nickel-titanium, stainless steel, and solder, which are placed in the fallopian tubes to induce fibrosis and block them to prevent fertilization.

Essure brought with it many promises: a perfect option for women looking out for a permanent surgical sterilization, and a perfect alternative to the then existing tedious tubal ligation procedure. The timing couldn't have been better. Essure qualified for all the 4 P's of marketing - Product, Price, Placement, and Promotion. It entered a ripe market that was willing, more than ever to use this new product. It wasn't surprising to know that Essure became the market leader, gaining prescriptions, in thousands, within a short span of time.

However, this rise was followed by a fall, when sales figures started plunging. Between 2002 and 2015, the company, itself, received more than 30,000 adverse event reports. No initiative was shown to resolve these. The list included persistent pain, perforation of the uterus and/or fallopian tubes, intra-abdominal or pelvic device migration, abnormal or irregular bleeding, and allergy or hypersensitivity reactions, including reports of unintended pregnancies.

Despite such grave complaints, the product wasn't withdrawn from the market. Subsequently, FDA passed an order for the product package to carry a 'black box' warning, a patient checklist to be completed by the patient, and ordered Bayer to conduct a post-market surveillance.

Aggrieved women have taken Bayer to Court; lawsuits were filed across the country. To prevent duplicity and inconsistent ruling, Judge Smith from California, consolidated 11 Essure lawsuits in August 2016, as they had common factual and legal questions. The judge ordered these cases to proceed on the liability issue. This was followed by the coordination of 55 more cases, in November 2016. The ruling of the first case will be a turning point for the other, hundreds of pending cases. The long wait may end anytime; one verdict will change the fate of thousands. Be ready before the high tide of cases hit you. Get a quality medical review done for Essure Litigations, at a flat rate of $100 per review, from Neural IT, to plug every loophole and make it a watertight case. We invite you to benefit from our record review services.

For more information, on other Mass Torts please click here. You may email us at info@neuralit.com or call +1-844-NIT-TEAM (648-8326).


We are social:

Accreditations

HIPAA

Neural IT has successfully implemented HIPAA for securing Health records....

ISO 27001 Certification

Neural IT has successfully passed the ISMS re-certification audit and is now ISO 27001:2013 certi...

NSIC - CRISIL

NSIC-CRISIL has assigned a "SE 2A" rating to Neural IT, indicating a company with High Performanc...

Associations

CAALA

CAALA - "Neural IT is proud to be associated with CAALA (Consumer Attorneys Association of Los An...

CAOC

CAOC - "Neural IT is proud to be associated with CAOC (Consumer Attorneys of California) as a Ven...

NYSTLA

NYSTLA - "Neural IT is proud to be associated with NYSTLA (New York State Trial Lawyers Associati...

News & Events

Hurricane Relief Fund
We donated to Hurricane Relief Fund and got a signed ball from Kareem Abdul-Jabbar, the greatest
AAJ Annual Convention 2017
Neural IT sponsored TRT meeting was one of the active participants of AAJ Annual Convention 2017.
NJAJ Boardwalk Seminar 2017
Neural IT exhibited at the NJAJ Boardwalk Seminar 2017 held at Harrah's Resort, Atlantic City, NJ

Latest Tweets